Neuro-oncology
Clinical research includes treatment strategies for recurrent glioblastoma, with interest in combining stereotactic radiotherapy and immunotherapy to address aggressive central nervous system disease.
- Glioblastoma
- Anti-PD-L1 therapy
- Radiotherapy
The sponsor also supports work in pediatric neuroblastoma, including peptide receptor radionuclide therapy for recurrent or refractory disease.
Head and neck oncology
Research activity covers head and neck squamous cell carcinoma, with emphasis on PD-L1-positive recurrent or metastatic disease and treatment combinations involving pembrolizumab and chemotherapy.
- Head and neck cancer
- Squamous cell carcinoma
- Immunotherapy
Additional interest extends to symptom control in the head and neck setting, including neuropathic pain management after cancer treatment.
Genitourinary and breast cancers
The sponsor funds studies in high-risk and locally advanced prostate cancer, focusing on peri-operative treatment approaches alongside surgery.
- Prostate cancer
- Breast cancer
- Targeted therapy
In metastatic breast cancer, research includes the clinical behavior of trastuzumab deruxtecan and its relationship to patient characteristics and treatment exposure.
Sarcoma oncology
Clinical studies address both soft tissue sarcoma and metastatic sarcoma, with interest in integrating peri-operative chemotherapy, systemic therapy, and stereotactic radiotherapy.
- Soft tissue sarcoma
- Metastatic sarcoma
- Chemotherapy
These studies reflect involvement in both resectable and advanced sarcoma settings, including approaches aimed at improving disease control.
Supportive care and symptom management
Research also includes control of neuropathic pain in patients with ORL cancer in remission, with attention to non-surgical supportive treatment options.
- Neuropathic pain
- Supportive oncology
- Remission care
This area complements the sponsor’s cancer research portfolio by addressing persistent treatment-related symptoms in survivors of head and neck cancer.
